Default company panoramic image
Logo

ArborVita Associates

ArborVita Associates is a biotechnology company that has developed a simpler, faster, and cheaper way to modify DNA using a patented enzyme

  • Stage Full Product Ready
  • Industry Biotechnology
  • Location United States
  • Currency USD
  • Employees 2
  • Website arborvitaassociates.com

Company Summary

Gene modification is the driving force behind nearly all modern biomedical discoveries. However despite the widespread scientific discoveries that GM tools have produced, the standard methods to achieve gene modification are slow, costly, and have not advanced significantly in decades. AVA’s DRAP enzyme solves the inefficiencies of gene modification, with immediate applications in drug development, gene therapy, and biomedical research.

Team

  • Default avatar
    John Nelson
    President

    Mr. Nelson is a current MBA candidate at the University Of Chicago Booth School Of Business. He spent over 5 years working at Oakwood Global Finance, a private equity firm in London, England. He is also the co-founder of a successful online educational business, UniversityTutor.com, a leading online marketplace for tutors. John graduated from Rice University with a degree in Economics in 2005.

  • Default avatar
    Michael Seiler
    VP

    Dr. Seiler earned his Ph.D in cell and molecular biology from the Baylor College of Medicine with post-doctoral studies at the University of Chicago. He has over 13 years’ experience in biomedical research, authored fourteen publications and has been recognized with NIH pre- and post-doctoral fellowships, and the excellence in research award from the American Society of Gene Therapy.

  • Default avatar
    Andrew Eisen
    CSO

    Dr. Eisen, the inventor of DRAP, holds an MD and PhD (Biophysics) from the University of Pennsylvania and has over 30 years of post-graduate biomedical experience. He trained at the Children’s Hospital of Philadelphia and the NIH. He was an Assistant Professor of Pediatrics & Molecular Genetics at the Albert Einstein College of Medicine. Dr. Eisen has 13 years’ private sector experience in both the Pharmaceutical and Biotech industries.

  • Default avatar
    Bruce Nelson
    Chairman/Interim CEO

    Mr. Nelson holds an MBA from the University Of Chicago Booth School Of Business and has over 40 years of experience in finance and management. He was VP and treasurer of The Rockefeller Group and President of Rockefeller Group Capital Corp. He is currently the founder and CEO of the private equity group Roundtree Capital.

Advisors

  • Default avatar
    Teddy C. Scott, Jr., Ph.D., Polsinelli Shughart PC
    Lawyer
    Unconfirmed

Previous Investors

  • Default avatar
    Bruce Nelson
    Unconfirmed
    Default avatar
    Eisen Family Fund
    Unconfirmed
    Default avatar
    University of Chicago Booth School of Business
    Unconfirmed